BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Life Stem Genetics, Inc. (OTCBB:LIFS) announced today a strategic collaborative agreement with American CryoStem Corporation, (OTCBB:CRYO). CRYO is a leading developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries.
Adipose tissue is an anatomical term for loose connective tissue (fat) composed of adipocytes (cells). It is used in LIFS stem cell procedures and currently is extracted via liposuction each time a patient has a treatment. This collaboration will give our physician’s network the ability to store a patient’s adipose tissue for future regenerative medicine applications after only one extraction process. In the absence of future liposuction procedures, the patient’s recovery time is lessened and additional procedure costs are reduced.
This collaboration will provide the Company’s physicians and medical clinics access to a FDA registered laboratory and the science of tissue collection, processing and long term storage of their patient’s adipose tissue sample collected at the point of care.
American CryoStem’s ATGRAFT™ tissue samples are processed and prepared upon arrival at their FDA registered laboratory based in Mt. Laurel, N.J., tested for adipocyte and cellular viability, and stored free of charge for six months. Long term storage fees will be billed directly to the patient by American CryoStem with revenue shared with LIFS. Stored patient samples retrieved by LIFS physicians will be shipped, ready for use without any additional processing.
Life Stem Genetics Chief Medical Stem Cell Specialist, James Vanden Bosch, BHA, commented, “This relationship secured with American CryoStem by Life Stem Genetics advances our physician’s treatment protocols from traditionally collecting and processing patients adipose tissue in the same day to establishing a treatment program not dictated by a single liposuction procedure.” Mr. Vanden Bosch further commented, “Patients can now visit a clinic and have future treatments with the same high quality adipose tissue.” he adds.
The Company expects to begin internal validation of the ATGRAFT™ service in the coming weeks prior to a full roll-out of this new offering. Additional updates about Life Stem Genetics and American CryoStem will be announced as this synergistic relationship continues to develop.
About Life Stem Genetics
Life Stem Genetics ("LSG") is a progressive healthcare company focused on Adult Stem Cell (ASC) healing therapies. For decades, stem cells have been utilized in the successful treatment of a variety of ailments. Today, advanced ASC therapies are being offered to patients as an efficient and painless alternative treatment for a wide range of ailments including, but not limited to, orthopedic injuries, neurological disorders such as Parkinson's and Alzheimer's, cancer, arthritis, diabetes, multiple sclerosis, as well as age management. Adult Stem Cell therapies and LSG's proprietary techniques are experiencing some of the best results in the industry in helping to repair or reprogram damaged or diseased tissues and organs. Life Stem's ASC specialist has performed thousands of stem cell treatments including some of the top names in PGA golf, NFL football, NBA basketball, and Major League Baseball. LSG will offer its proprietary treatments through a series of affiliate doctors and medical clinics with 60 affiliated clinics thus far. LSG's mission is to develop a comprehensive approach to the treatment and maintenance of diseases while breaking free from the medical insurance maze by tapping into an affordable private-pay sector.
Contrarian Press, an established publisher, has been engaged by Life Stem Genetics to assist with identification of potential market participants who may be interested in learning more about the company and its securities. Updated disclaimer and disclosure information is available at the publisher's website and at the following link: http://www.contrarianwealthcoalition.com/guide/LIFS.pdf
For a copy of LIFS logo is available at: http://www.lifestemgenetics.com/wp-content/themes/LifeStemGenetics/images/life-stem-genetics-logo.png
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem Corporation is engaged in building a worldwide network of state-of-the-art clinical laboratories dedicated to processing, commercial bio-banking and manufacturing cellular applications using autologous adipose (fat) tissue and Adipose-Derived Regenerative Cells (ADRCs). The Company maintains a strong, strategic portfolio of intellectual property, patent applications and proprietary operating procedural processes that form its Adipose Tissue Processing Platform, which in turn, supports the growing pipeline of biologic products and processes, clinical services and international licensing opportunities. More specifically, this platform enables the cryopreservation of an individual's adipose tissue which when needed can be further clinically processed into Stromal Vascular Fraction (SVF), which contains ADRCs, other regenerative cells, including white blood cells, endothelial cells, smooth muscle cells, pericytes, fibroblasts and pre-adipocytes, among others. Through its ACS Laboratories division, the Company operates its flagship FDA registered, cGMP compliant human tissue processing, cryo-storage and cell culture and differentiation media development facility in Mount Laurel, New Jersey.
Forward Looking Statements
This press release may contain forward-looking statements, including information about management's view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may", "could", "estimates", "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and the Company's future performance, operations, and products. Such statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to differ materially from the results expressed or implied by such statements. Such risks and uncertainties include, without limitation, market acceptance of the Company's stem cell therapy treatment program; the Company's compliance with applicable statutes and regulations: the Company's reliance on third-party contractors to provide suitable treatment facilities; the Company's ability to expand its network of participating clinics and doctors; the Company's ability to develop an effective marketing strategy; the Company's ability to control and reduce advertising and marketing costs; the Company's ability to develop and increase awareness of its brand; the Company's ability to protect its trademarks; and the success of the Company's marketing focus to patients, doctors and clinics. For a discussion of these and other risks and uncertainties see "Risk Factors" and "Description of Business" in the Company's public filings with the SEC. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.